News
Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK
Additional space will provide purpose-built research laboratories accommodating around 450 scientists at Immunocore
Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, and MEPC Limited (MEPC), a leading property developer and asset manager, announced today that Immunocore will expand its operations at Milton Park in Oxfordshire initially by a further 53,000 square feet (sq ft). The new purpose-built research laboratory facilities will support Immunocore’s continued growth in the area.